Statement Of Cash Flows [Abstract]

Medicover - Filing #679259

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income (cost)
470,000,000 EUR
318,000,000 EUR
Cash flows from (used in) operations before changes in working capital
2,194,000,000 EUR
2,098,000,000 EUR
Adjustments for decrease (increase) in trade and other receivables
291,000,000 EUR
267,000,000 EUR
Adjustments for increase (decrease) in trade and other payables
198,000,000 EUR
256,000,000 EUR
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss
1,824,000,000 EUR
1,619,000,000 EUR
Cash flows from (used in) investing activities [abstract]
Dividends received from associates, classified as investing activities
1,000,000 EUR
1,000,000 EUR
Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations
14,000,000 EUR
30,000,000 EUR
Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets
1,105,000,000 EUR
1,406,000,000 EUR
Purchase of investments other than investments accounted for using equity method
EUR
5,000,000 EUR
Purchase of financial instruments, classified as investing activities
210,000,000 EUR
63,000,000 EUR
Proceeds from sales or maturity of financial instruments, classified as investing activities
EUR
5,000,000 EUR
Cash flows from (used in) financing activities [abstract]
Dividends paid to non-controlling interests, classified as financing activities
38,000,000 EUR
60,000,000 EUR
Proceeds from contributions of non-controlling interests
EUR
8,000,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.